## ILMN: Illumina, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($121.18)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Illumina To Webcast Upcoming Investor Conference**
- Source: WOWK 13 News | 20251216T210918 | Neutral | Relevance: 100%
- Illumina, Inc. (NASDAQ: ILMN) announced its management team will attend the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation and Q&A session will be webcast live on Illumina's investor relations website, with an archived replay available for at least 30 days. This conference provides an opportunity for investors to hear directly from Illumina's leadership about their genomic solutions and future outlook.

**2. Scott Davies Sells 323 Shares of Illumina (NASDAQ:ILMN) Stock**
- Source: MarketBeat | 20251217T060918 | Neutral | Relevance: 100%
- Illumina insider Scott Davies sold 323 shares of the company's stock on December 12th at an average price of $136.09, totaling $43,957.07, reducing his stake by 1.77%. Despite the insider sale, Illumina recently traded near $131.56 after exceeding Q3 earnings estimates and providing strong FY2025 guidance. The company holds an average analyst rating of "Hold" with a target price of approximately $117.19, and institutional investors have been actively adjusting their positions.

**3. Meet three scientists behind Illumina’s spatial assay breakthrough**
- Source: Illumina | 20251216T190918 | Bullish | Relevance: 100%
- Three Illumina scientists—Anustup Poddar, Andrea Manzo, and Chris Beierschmitt—have developed a groundbreaking spatial assay technology that enables high-resolution RNA sequencing within tissue samples, launching officially next year. This innovation allows researchers to map gene activity with remarkable spatial resolution, significantly advancing the understanding of complex biological systems for research and clinical applications. Beyond their scientific contributions, the team fosters a strong culture of collaboration, mentorship, and community service, regularly volunteering to inspire future STEM leaders.

**4. United States DNA Sequencing Market 2031 | Growth Drivers, Key Players & Investment Opportunities | Leading Companies - Bio-Rad Laboratories Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche, Illumina Inc.**
- Source: openPR.com | 20251215T120923 | Bullish | Relevance: 100%
- The United States DNA Sequencing Market is expected to grow at a CAGR of 11.3% during the forecast period (2024-2031). Recent developments include Illumina's collaboration with MyOme and acquisition of SomaLogic, and Pacific Biosciences' updates to its Revio sequencing system, all aimed at advancing genomic applications and personalized medicine. Key market players include Illumina Inc., Danaher Corporation, and Thermo Fisher Scientific Inc., with North America holding the largest market share due to its advanced healthcare infrastructure and genomics research funding.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $110 | $100 | +10% |
| 2025-12-15 | JP Morgan | $130 | $105 | +24% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Underweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.09M) |
| Sells | 10 ($80.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Capital World Invest: 13.1% (+20.0%)
- Blackrock Inc.: 12.2% (-3.5%)
- Vanguard Group Inc: 9.6% (-3.5%)
- State Street Corpora: 3.9% (+6.8%)
- Sessa Capital IM, L.: 3.1% (-0.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.2% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $80M sold (10 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 25.9x stretched relative to 6% growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (2 raises, avg +17%). Insider selling cluster ($80.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.9B |
| Beta | 1.44 |
| 52W Range | $68.70 - $153.06 |
| Short Interest | 7.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 25.9 |
| Current P/E | 27.5 |
| YoY Growth | 6.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 4.2% to 1.1% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.9pp (needs >3.0% for momentum thesis). MRS_5 (-1.1%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.65), momentum weakening. RSI neutral at 56. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.08% (CS: 35) | Neutral |
| RSI_14 | 56.2 | Neutral |
| MACD Histogram | -0.65 | Bearish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.116x | Above |
| vs SMA200 | 1.343x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $129.56
- **Stop Loss:** $121.18 (6.5% risk)
- **Target:** $137.94 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 128
- **Position Value:** $16,583.68
- **Portfolio %:** 16.58%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-05 (Est: $1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.34 | +14.7% |
| 2025Q2 | $1.01 | $1.19 | +17.7% |
| 2025Q1 | $0.94 | $0.97 | +3.3% |
| 2024Q4 | $0.92 | $0.86 | -6.8% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*